Apolipoprotein E/ApoE Antibody (3D12)

Immunohistochemistry: Apolipoprotein E/ApoE Antibody (3D12) [NBP1-97424] - Abeta12-28P treatment reduces soluble and insoluble brain apoE levels and apoE deposition in Abeta plaques in APP/E2 and APP/E4 mice. Representative microphotographs of coronal sections through the sensorimotorcortex at the level of the posterior caudate-putamen from vehicle- and Abeta12-28P-treated APP/E2 and APP/E4 mice, whichwere immunostained against human apoE. White arrowheads indicate apoE positive deposits. Scalebar 200 um. Abbreviations: cc, corpus callosum; CPu, caudate-putamen; NCtx, neocortex. Image collected and cropped by CiteAb from the following publication (actaneurocomms.biomedcentral.com/articles/10.1186/s40478-014-0075-0), licensed under a CC-BY license.

Immunocytochemistry/ Immunofluorescence: Apolipoprotein E/ApoE Antibody (3D12) [NBP1-97424] - A beta 12-28P treatment reduces soluble andinsoluble brain apoE levels & apoE deposition in A beta plaques in APP/E2 & APP/E4 mice. Levels ofsoluble (diethylamine-extractable) human apoE (A) & those of insoluble(formic-acid-extractable) human apoE (B). Values are mean (±SEM) in 11–12 animalsof APP/E2 background & 8 animals of APP/E4 background.(C) Representativemicrophotographs of coronal sections through the sensorimotorcortex at the level of the posterior caudate-putamen fromvehicle- & A beta 12-28P-treated APP/E2 & APP/E4 mice, whichwere immunostained against human apoE. White arrowheadsindicate apoE positive deposits. (D) Mean (±SEM) human apoE positive plaqueload in the neocortex & the hippocampus (n = 7–8/group).(A, B, D) * p < 0.05, ** p < 0.01, *** p < 0.001, *** p < 0.0001, versusvehicle-treated mice of the same APOE background (Student’st test).##p < 0.01,####p < 0.0001,vehicle-treated APP/E2 mice vs. vehicle-treated APP/E4 mice(Student’s t test). Scalebar 200 μm (C).Abbreviations: cc, corpus callosum; CPu, caudate-putamen;NCtx, neocortex. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24972680), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Product Discontinued

Apolipoprotein E/ApoE Antibody (3D12) Summary

• Description: Please note the 0.5ml size comes in reconstituted form.
• Immunogen: Apolipoprotein E/ApoE
• Specificity: The antibody reacts with very low density lipoproteins (VLDL) of human plasma. It is specific for human apo-E. No cross reactions with other human plasma proteins were detected. This antibody reacts as well with LDL as with VLDL. This antibody recognizes all alleles of APO-E.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: APOE
• Purity: Sodium sulfate precipitation

Applications/Dilutions

• Dilutions:
  • ELISA 1:1000
  • Immunohistochemistry 1:25
  • Immunohistochemistry-Frozen 1:25
  • Western Blot
• Application Notes: In combination with other mabs for detection of VLDL in plasma, and for the specific detection of apo-E. The antibody is also useful for detection of apo-E in tissue sections. The antibody can be used in ELISA techniques and in immunohistochemistry on frozen sections and possibly on paraffin embedded tissues. For application on paraffin embedded tissues an optimal dilution has to be determined within each laboratory. For depletion experiments the antibody should be used in a solid phase system.

Reactivity Notes

Mouse reactivity data from actaneurocomms.biomedcentral.com/articles/10.1186/s40478-014-0075-0.

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: Lyophilized from 0.01M sodium phosphate, 0.01M sodium borate, 0.15M sodium chloride, pH 8
• Preservative: 1% Dextran, 1% Mannitol
• Purity: Sodium sulfate precipitation
• Reconstitution Instructions: Reconstitute in 1 ml sterile pure water

Notes

Please note the 0.5ml size comes in reconstituted form.

Alternate Names for Apolipoprotein E/ApoE Antibody (3D12)

• APOE
• Apo-E
• Apolipoprotein E
• apolipoprotein E3
• late onset)
• MGC1571

Background

The low density lipoprotein (LDL) receptor system coordinates the metabolism of cholesterol, an essential component of the plasma membrane of all mammalian cells. Study of this system has led to an enhanced understanding of the cellular basis of cholesterol homeostasis. It has also brought into focus an important mechanism of metabolic regulation--the process of receptor-mediated endocytosis (1). Data suggest that the juxtamembranous region of the cytoplasmic domain participates in protein:protein interactions that allow the low density lipoprotein receptor to cluster in coated pits (2). It has been shown that the family of LDL receptors may serve as viral receptors. Endocytosis of the Flaviviridae viruses, hepatitis C virus, GB virus C/hepatitis G virus, and bovine viral diarrheal virus (BVDV) was shown to be mediated by LDL receptors on cultured cells (3).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Apolipoprotein E/ApoE Antibody (NBP1-97424)(1)

Publication using NBP1-97424

• Blocking the apoE/A beta Interaction Ameliorates A beta-related Pathology in APOE epsilon 2 and epsilon 4 Targeted Replacement Alzheimer Model Mice Pankiewicz J, Guridi M, Kim J et al. Acta Neuropathol Commun. [PMID: 24972680] (IF/IHC, Mouse)

Bioinformatics

• Gene Symbol: APOE